Howard Kaufman

Howard Kaufman is a surgical oncologist and tumor immunologist who played a central role in developing T-VEC (talimogene laherparepvec), the first FDA-approved oncolytic viral therapy for melanoma. He has conducted extensive clinical investigation in melanoma and rare skin cancers including Merkel cell carcinoma, contributing to understanding of regional therapy and intralesional approaches. His laboratory studies how oncolytic viruses induce systemic immune responses and how they can synergize with checkpoint inhibitors. He is a frequent collaborator on melanoma and skin cancer clinical trials.